Meet our Experts

All of our courses are designed with, and taught by, an exclusive network of experts who are internationally recognised by their peers as opinion leaders in their field of expertise. These experts are sought-after by the industry for complex consulting projects and therefore have limited time for public speaking.

See below for each expert's biography and the training courses they deliver:

Lieven Annemans

Prof. Dr. Lieven Annemans

Lieven Annemans is a Senior Full Professor of Health Economics at the medical faculty of Ghent University in Belgium. He is Past-President of ISPOR, the International Society for PharmacoEconomics and Outcomes Research, and was advisor to the Belgian Minister of Health. He has experience in health economic evaluations and health technology assessments (HTA) of medicines, medical devices and preventive health actions in various medical areas, and conducted >300 studies in over 20 countries. He is currently also active as an independent consultant in health economics and prior to his professorship he has also worked in the pharma industry.

His main interests are epidemiological models, early-stage HTA, retrospective/ prospective health economic evaluations, and physician payment systems. He has published over 250 papers in peer-reviewed journals, and provides lectures and trainings on health economic evaluations and HTA. He is the author of the book Health economics for non-economists: an introduction to the principles, methods and pitfalls of health economic evaluations (Academia Press; 2008).

Prof. Annemans joined C.E.L.forpharma’s faculty in 2009. Since then he delivers the immensely popular course Health Economics for Non-Health-Economists and since 2014 also The HTA Course.

Prof John Weinman

Prof. John Weinman

John Weinman is Professor of Psychology as applied to Medicines at the Institute of Pharmaceutical Sciences and the Institute of Psychiatry, Psychology & Neurosciences at King’s College London, and is also Head of Health Psychology (Europe) for Atlantis Healthcare. The main focus of his research has been on the ways in which patients’ beliefs about their illness and treatment affect self-regulation and self-management, with a particular focus on treatment adherence, across a wide range of major physical health problems. This research has been published in a large number of papers in peer review journals, and has provided the basis for many successful interventions for supporting patient self-management and treatment adherence.

 He currently holds visiting professorships in University College London, Denmark and Ireland, and has been awarded a lifetime achievement award and an Honorary Fellowship by the British Psychological Society. He is a Fellow of the European Psychological Society, the American Academy of Behavioural Medicine Research, and the Academy of Social Sciences.

Prof. Weinman joined C.E.L.forpharma’s faculty in early 2014 and since then teaches on the Patient Adherence Course alongside Jeremy Sayers from Atlantis Healthcare. Their course unravels the mystery of patient non-adherence while offering methodologies and insights for pharma, when addressing that issue, through patient services.

Gary Johnson

Gary Johnson

As the founder and Managing Director of Inpharmation, a consultancy specialising in evidence-based prediction of sales demand and price elasticity for pharmaceuticals, Gary Johnson has been involved in pricing and/or forecasting of around half of the new molecular entity launches over the past five years.

Prior to founding Inpharmation, Gary spent two decades in the pharma industry holding senior positions, such as General Manager and Head of Global Marketing with a number of major blue-chip pharma companies, including SmithKline Beecham, Fisons and Schwarz. Gary Johnson is a sought-after industry speaker and conference chairman.

Gary is the author of Value Pricing for Market Access: Evidence-based pricing for pharmaceuticals and Sales Forecasting for Pharmaceuticals: An Evidence Based Approach - the definitive works on pricing and sales forecasting of pharmaceutical products. Other books include Monkey Business: Why the Way You Manage is a Million Years out of Date - finalist for the MCA Book Prize.

Gary Johnson joined C.E.L.forpharma’s faculty in 2007 and since then delivers the pharma industry’s only regular public course on evidence-based sales forecasting for pharmaceuticals. Since 2008 he also delivers the industry’s only regular public course on pharmaceutical value pricing. Both courses are organised in Brussels, London and Zurich.

fonny_schenk_new_2.jpg

Fonny Schenck

Fonny Schenck joined Across Health as CEO in 2007 after 20 years at Johnson & Johnson where he focused on salesforce effectiveness, CRM strategy and Digital at regional level.

At Across Health, he is now focused on helping international clients “fix the mix”, i.e. navigating towards a new commercial model, through the selective adoption of impactful innovative customer approaches … and moving these beyond the pilot stage into the DNA of leading companies, through an integrated mix of customer/market/technology insights, strategy, integrated execution, and impact measurement. Fonny likes to work at the exciting intersection of technology, commercial effectiveness, business strategy and innovation. Some of his more recent strategic focus areas include value-based approaches, e-medical affairs, connected health and healthcare disruption.

Fonny received many awards at J&J for his achievements in the CRM and digital space, both at European and global level. In addition, he is a well-known trainer and speaker at international events, and has authored several strategic articles on these topics.

Fonny joined C.E.L.forpharma’s faculty in 2010 and since then, together with his team at Across Health, championed the development of a successful series of courses related to the fusion of digital with pharma’s multi-channel communications mix in both marketing and medical affairs.

Dr Patrik Frei

Dr. Patrik Frei

Patrik Frei, PhD, is founder and CEO of Venture Valuation AG, specialists in independent, third party assessment and valuation of emerging high growth companies in biotechnology and life sciences. He founded his company in 1999, based on his research at the University of St. Gallen and EPFL Lausanne, for which he collaborated with Novartis Venture Fund, which became his first client. Since then he has been involved in over 400 valuations for investors as well as biotech, pharma and medtech companies. Venture Valuation also runs Biotechgate, a global company, investors and licensing deal database.

Patrik was a board member and one of the original founders of Ineo, a holding company of the Swiss dental implant VC-backed firm Thommen Medical. He was also the Chairman of Ophthalmopharma, a Swiss based biotech ophthalmology company, where he successfully out-licensed a portfolio of 4 products. Furthermore, Patrik is member of the board of Kleinkraftwerk Birseck AG, a publicly quoted cleantech company. Patrik’s articles have been published in a number of scientific journals including “Nature Biotechnology”, “Drug Discovery Today” and other business publications. He has also lectured at Seoul National University, South Korea, EPFL Lausanne, University of St. Gallen and gives regular workshops on valuation.

Patrik Frei is a faculty member of C.E.L.forpharma since 2007. He developed and delivers the Pharma-Biotech Company & Product Valuation course for audiences of biotech, pharma and tech transfer executives. He consistently gets top ratings for his course.

Dr. Neal Hansen

Dr. Neal Hansen

Neal Hansen, PhD, is the Managing Director of Align Strategy, an independent international consulting business focused on advising and facilitating superior decision making in lifecycle management and brand strategy. Neal has worked with many of the leading pharmaceutical and biotech companies, supporting pipeline, in-line and established brand planning, with a focus on competitive simulations, late stage lifecycle management (LCM) and emerging markets.

Prior to establishing Align Strategy and its predecessor Hansen Strategy, Neal was the Global Director of Healthcare Consulting within the Informa Group, leading both Phasic Strategy and Datamonitor Healthcare Consulting.

In this role and his previous role as the European Head of Consulting for Wood Mackenzie, Neal led commercial assessment, scenario planning and war gaming projects for numerous top tier and mid-cap pharmaceutical companies in Europe, the US and Japan. Earlier in his career, Neal held various senior roles within Datamonitor, including Lead Consultant and Lead Analyst for Strategic and Company Intelligence.

In 2012, he co-authored Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand (Wiley & Sons, 2012) and has previously authored several in-depth analyses on strategic issues affecting the pharmaceutical industry, focusing on LCM, pharmaceutical sales force strategies, competitive dynamics in mature and emerging markets and the changing nature of the global generics sector. He has chaired and spoken at numerous conferences in the field of LCM and the changing nature of the generics industry. His work has featured in Scrip, The Economist and The Wall Street Journal.

Neal Hanssen is the master mind and speaker of C.E.L.forpharma LCM courses since 2007. His course always gets top ratings and is consistently highly praised by portfolio managers of mature/established brands.

Annelien Van Boxlaer

Annelien Van Boxlaer

Annelien Van Boxlaer is VP of Innovation Strategy for Across Health, where she joined as a senior consultant in 2013. Annelien has extensive expertise in developing cross-channel strategies and impact measurement, as well as brand strategy, customer intelligence and multi-channel rep strategy.

Prior to joining Across Health, Annelien was a brand and marketing manager at AstraZeneca where she worked in several therapy areas and lifecycle stages. She was also involved in international teams which exposed her to many multi-channel projects and approaches. Prior to AstraZeneca, Annelien was a consultant at McKinsey & Co, with a strong focus on marketing and sales projects in pharma.

Annelien joined C.E.L.forpharma's faculty in 2016 and co-leads The Strategic Digital Pharma Marketing Course with Ruud Kooi.

Ben Harbour

Ben Harbour

Ben Harbour is Across Health’s Managing Director for the United Kingdom and brings with him more than 18 years of healthcare experience.

Ben has held sales and research positions within the pharmaceutical industry before focusing on global medical communications. Throughout this time, he has worked extensively throughout Europe, US and the emerging markets, providing the pharma, biotech and medical device industries with strategic guidance on a range of multichannel communication programmes at a corporate, regional, and brand level. His experience spans the clinical, medical and commercial phases of product development across a wide range of therapeutic indications. This end-to-end perspective has helped him to develop a clear understanding of client needs, allowing him to quickly get to the heart of critical scientific and commercial issues.

Ben Harbour joined C.E.L.forpharma’s faculty in 2015 and delivers, alongside Fonny Schenck, the e-Medical Affairs course which teaches the integration of digital in the overall medical affairs strategy and medical plans.

Beverly Smet

Beverly Smet

Beverly Smet is a Vice President with Across Health and has a proven track record in the life sciences industry, with particular expertise in multichannel strategy and campaign management, virtual selling models, closed loop marketing and fusion med-ed strategies.

During the past decade, Beverly has also worked as a dedicated digital marketing consultant for the EMEA Web & Multichannel team of Johnson & Johnson as well as for some other top 10 pharma companies. Next to fusion marketing consultancy, Beverly has also been a speaker at international events such as eyeforpharma and NextLevel Pharma. Before his activities at Johnson & Johnson, Beverly worked five years for Royal Numico, a market leader for baby and clinical nutrition, where he created a world-class CRM loyalty model for young and expecting parents.

Beverly Smet joined C.E.L.forpharma’s faculty in 2014 on digital marketing programmes. He championed the development of the The Multi-Channel Patient Engagement Course which teaches hands-on methodologies that are backed up by patient research findings and that use digital multi-channel tactics to activate patients and to support them in their therapy. Beverly is amongst our highest rated speakers.

Chris Toller

Chris Toller

Chris Toller is a leading international consultant in pharmaceutical medical affairs. 

Educated at Westminster Medical School, London, Chris left clinical medicine in the 1980s and founded MEDIQ Ltd – one of the UK’s first specialist medical communications agencies.  Over the next 15 years, Chris led teams in the UK and USA that devised medical affairs strategies and implemented programmes for most of the world’s top 20 pharma companies.  As well as making important contributions to over 100 different medical brands, his skills have also been utilized by smaller companies and biotech start-ups – acting as a virtual medical affairs department. After the success of MEDIQ, Chris spent 2 years directing medical and commercial strategies for a US-based private biotech company before he joined the Choice Group in 2010.  Initially, he led the international medical communications business, Choice Healthcare Solutions, and was then invited onto the Group board as Head of Strategy in 2012. 

Throughout his career, Chris has had experience in just about every therapy area, and has worked with medical affairs teams in Europe and the USA as well as emerging markets in Asia-Pacific and the Middle East. He has a reputation as a creative strategic thinker, an excellent communicator and an inspirational presenter.

Chris Toller joins C.E.L.forpharma’s faculty in 2016 with the launch of the Medical Affairs for Modern Pharma course. 

David Scott

David Scott

David Scott is a Licensing and Business Development consultant and a skilled negotiator who has closed a number of major deals for inward and outward licensing for pharmaceutical products, delivery systems and technologies. He has published widely and his best-selling report Scrip's Practical Guide to Pharmaceutical Licensing has been regarded by the international pharma-biotech licensing community as the quintessential reference for almost two decades.  

David is also an accredited Certified Licensing Professional and a member of the Licensing Executives Society and of the Pharmaceutical Licensing Group. He has spent the past 20 years as a freelance consultant for a range of worldwide clients, including top-ranking global companies, European regional companies, biotech companies, technology start-ups and universities. He currently sits on the board of two UK-based pharmaceutical businesses.

David Scott joined C.E.L.forpharma’s faculty in 2010 and since then delivers the only public course on pharmaceutical out-licensing. He provides carefully structured presentational material which he illustrates with personal examples.

Nick Proctor

Dr. Nick Proctor

Nick Proctor, PhD in Pharmacy, is a Director at Adelphi Access and has been a consultant to the pharmaceutical industry for over 17 years in areas ranging from the pre-clinical/FTIM interface, through clinical development and launch, to late lifecycle management. Over the past 9 years, he has led pricing, reimbursement and access projects for the majority of the world’s top pharmaceutical brands and manufacturers.

In addition to strategic pricing, Nick has a strong background in evidence synthesis, health economics and outcomes research as well as experience of working with payers in all major developed and emerging international health markets.

Nick Proctor joined C.E.L.forpharma’s faculty in 2015 and together with Mark Silvey delivers the highly praised Pharma Market Access course. 

Dr. Roger Cox

Dr. Roger Cox

Roger Cox, PhD, has a 30-year career in business development within the healthcare industry, most recently with Johnson & Johnson as Executive Director, Licensing in J&J's worldwide Pharmaceuticals Business Development Group. He is currently a Senior Consultant with Plexus Ventures, a leading global pharmaceutical business development firm.

His broad experience in the industry includes licensing and business development with a small pharmaceutical company (Medgenix Group), managing investments in unlisted biotechnology companies as a Senior Investment Executive at British Technology Group, and being Commercial Director of the Cambridge-based immunodiagnostics company (IQ (Bio) Ltd).

Roger Cox was co-founder of the Pharmaceutical Licensing Group Benelux, Chairman of the European Pharmaceutical Licensing Council (2007-2009) and Member of the Editorial Board of the Business Development & Licensing Journal for the Pharmaceutical Licensing Groups.

Since 2013 Roger Cox has been presenting a negotiation course on pharmaceutical licensing for C.E.L.forpharma. The course is popular with Business Development and Licensing Executives from all parts of the Pharma and Biotech industries and is held 3x a year in Brussels, Zurich and London.

Edouard Demeire

Edouard Demeire

Edouard Demeire uniquely combines in-depth pharma marketing expertise with academic rigour and a wealth of training experience all over the globe. His teaching, consulting and research focus is on systematic decision support tools and models for pharma marketing strategy.

Edouard has trained well over 5000 executives in the pharmaceutical industry. He is a Visiting Professor at CEDEP/INSEAD in Fontainebleau and Solvay Business School in Brussels. In addition, he has run hundreds of workshops at AZ, Eli-Lilly, MCE, Novartis, Organon & Schering-Plough (now MSD), Roche, as well as with many medium-sized pharmaceutical companies.

He co-authored a number of articles, marketing decision support systems and business simulations for the pharma industry with Prof. Marcel Corstjens of INSEAD. Edouard is co-author of GOOD PHARMA. How Marketing Creates Value in Pharma (Corstjens & Demeire, 2014) and he also developed the brand plan quality checklist, a tool for assessing the quality of your brand plans.

Edouard Demeire co-founded C.E.L.forpharma in 2005 and since then delivers The Pharma Brand Planning Course, an evergreen course that is highly valued by anyone wishing to build a career in pharmaceutical marketing. Since 2016, Edouard also delivers the new course Pharmaceutical Marketing for Non-Marketing Functions

Jeremy Sayers

Jeremy Sayers

Jeremy Sayers has spent the last 5 years at Atlantis Healthcare, designing and implementing global, regional & local patient services/programmes alongside Professor Weinman and the health psychology team. His unique experience in this innovative space has led him to encounter many of the challenges that pharmaceutical companies come across when implementing a service, along with optimal methodologies to overcoming them. Having worked with a whole spectrum of healthcare stakeholders, from industry to provider to payer, Jeremy also has a solid grasp of how patient services can be integrated into existing health systems.

Jeremy Sayers joined C.E.L.forpharma’s faculty in early 2014 and has championed the Patient Adherence Course since then. This course, which he delivers with Prof. John Weinman, is the only public course that unravels the mystery of patient non-adherence while offering methodologies and insights for pharma, when addressing that issue, through patient services.

Mark Silvey

Mark Silvey

Mark Silvey is a Director at Adelphi Access and has worked with the pharmaceutical industry for 19 years.  He provides strategic market access consultancy advice across a wide range of clients and therapy areas to help clients understand and respond to the market access challenges that they are likely to face with their brands.

Mark is responsible for leading international projects in market access and real world evidence. His previous experience encompasses market research, medical communications and strategic planning which enables him to deliver a wide strategic view of market access.

Mark Silvey joined C.E.L.forpharma’s faculty in 2011. His up-to-date knowledge of the European healthcare systems has been highly valued by our audiences of the Pharma Market Access course ever since.

Martin Austin

Martin Austin

Martin Austin has over 35 years of senior executive experience in the pharmaceutical and healthcare industries. Between 1996 and 2000, he was Roche’s global Head of Business Development for Pharmaceuticals. During that period he had a leading role in the establishment of Roche Genetics, the rationalization of the R&D portfolio which led to the establishment of companies such as Actelion and Basilea, as well as in the acquisition and integration of Boehringer Mannheim. After that, until January 2005, he was a Principal with Paul Capital Partners, a global private equity firm, leading their European Royalty healthcare activities. Since 2005, Martin has worked as an independent advisor providing strategic insight and practical support to clients regarding investments and business development opportunities,

Martin is the author of Business Development for the Biotechnology and Pharmaceutical Industry (Gower, 2008) and Licensing, Selling and Finance in the Pharmaceutical and Healthcare Industries (Gower, 2012). He is also a Partner in Marram Advisors, a Swiss investment firm, and serves as a Board Member of several biotechnology companies.

Martin Austin has been on C.E.L.forpharma’s faculty since its foundation in 2005 and delivers the very popular The Pharma Business Development Course, a highly praised overview course. 

Prof. Dr. Brian D. Smith

Prof. Dr. Brian D. Smith

Brian Smith is an academic, author and advisor in the area of competitive strategy and has been described as the world’s leading authority on the evolution of the life sciences sector. He has eighteen years research experience at Europe’s leading business schools, has published over 300 books, papers and articles and provides strategy advice to many global companies in the pharmaceutical and medical technology sectors. Professor Smith’s research and publications provide a continuing opportunity to develop a coherent understanding of how the pharma and medtech industry is changing.

Professor Smith is a professor at SDA Bocconi, Milan and University of Hertfordshire, UK, where he leads the Future of the Life Sciences Industry research group. This follows on from 20 years’ experience in the pharma and medical device industry, first as a research chemist and then in an ascending series of marketing roles. He is the author of The Future of Pharma: Evolutionary Threats and Opportunities (Gower, 2011) and of Darwin’s Medicine: How Business Models in the Life Sciences Industry are Evolving (Gower, Nov. 2016).

Prof. Smith joined C.E.L.forpharma’s faculty in 2016 and delivers the thought provoking and very inspirational seminar Transforming Your Pharma & Medtech Business Model.

Ruud Kooi

Ruud Kooi

Ruud Kooi is a Vice President at Across Health and has over 20 years of experience in the pharmaceutical industry.

During the first 10 years of his career, Ruud worked for Janssen in the industry’s leading Janssen Digital and eBusiness teams, responsible for igniting regional projects, pilots and programs, plus a flawless execution and leverage at local affiliate level. In the last 10 years of his career, Ruud worked at Across Health and specialized in fusing digital and multichannel communication with the traditional offline communications mix in the pharma industry. Ruud has created many strategies with a strong digital component, aimed at achieving objectives at the company, franchise or brand level, through personal and digital interactions. He also led several implementation programs turning the strategy into reality. His vast experience in both strategy design and implementation is demonstrated by the many practical examples he discusses during his course. 

Ruud Kooi has been providing training for over 10 years and joined C.E.L.forpharma’s faculty in 2012. He spearheaded the development of The Strategic Digital Pharma Marketing Course, which has become immensely popular because of its strategic content and top-notch quality. Ruud is consistently rated as top trainer by his classes.

Stefan Gijssels

Stefan Gijssels

Stefan Gijssels is a consultant, coach and facilitator in the area of public affairs and reputation management. After 13 years as Vice President Public Affairs at the Janssen Pharmaceutical Companies of Johnson & Johnson, Stefan set up his own consultancy in 2016, primarily offering services to the pharmaceutical industry. At Janssen, he led a team of 66 public affairs and communications staff in the Europe, Middle East & Africa region, leading the company’s global reputation management programme. 

Stefan Gijssels held various positions in industry and public policy organisations, including Chairman of the Trust & Reputation Policy Committee of the European Federation of Pharmaceutical Industry and Associations (EFPIA). He was Public Affairs Manager at McDonald’s and consultant at Weber Shandwick and Burson-Marsteller, after several years as Project Manager at the Institute of the Enterprise. 
He has a master's degree in Literature & Linguistics from the University of Leuven, Belgium. 

Stefan Gijssels joined C.E.L.forpharma’s faculty in 2016 and delivers the thought provoking and very inspirational seminar Improve Reputation for Better Results in Pharma.

Steve Fermer

Steve Fermer

Steve Fermer is the Adelphi Real World Innovation Director. Steve has worked in real world research and consulting since 2005. His previous career spanned healthcare provision in the developing world, scientific publishing and pharmaceutical communication strategy.

Before joining Adelphi, Steve was Managing Director of a leading healthcare communications agency of 100 employees. Steve has worked with all of the leading pharmaceutical companies, at a global level, providing strategic counsel to a wide range of internal functions (marketing, R&D, medical affairs, HEOR and increasingly RWE).

Steve and Tim joined C.E.L.forpharma’s faculty in 2016 and deliver the first-ever course on the topic of Real World Evidence.

* Adelphi has a 20+ year heritage in conducting Real World studies in Europe, USA, the Far East and Latin America through the Adelphi Real World Disease Specific Programmes® (DSPs) and Bespoke Solutions. DSPs have wave on wave trend data available for analysis in more than 50 distinct disease areas. The collection of data is undertaken from physicians (primary care/specialists), patients (including validated PROs), carers and payers. Adelphi Real World has 350+ publications in over 40 peer-reviewed journals and more than 100 scientific congresses worldwide. These publications have been used in therapy guideline evolution and regulatory submissions.

Tim Holbrook

Tim Holbrook

Tim Holbrook is the Adelphi Real World Health Economics and Outcomes Research Associate Director.

Tim has over 8 years of experience applying economic modelling to healthcare and public health decision-making, delivering informative and meaningful health economic evidence and strategic recommendations to decision-makers for both the UK National Health Service and pharmaceutical companies.

Tim has worked with a variety of types of real world data, including their integration to meet difficult objectives, and has accessed and analysed data from across Europe, North America, and East Asia. Dozens of his peer-reviewed journal articles and HTA submissions have been published.

Steve and Tim joined C.E.L.forpharma’s faculty in 2016 and deliver the first-ever course on the topic of Real World Evidence.

* Adelphi has a 20+ year heritage in conducting Real World studies in Europe, USA, the Far East and Latin America through the Adelphi Real World Disease Specific Programmes® (DSPs) and Bespoke Solutions. DSPs have wave on wave trend data available for analysis in more than 50 distinct disease areas. The collection of data is undertaken from physicians (primary care/specialists), patients (including validated PROs), carers and payers. Adelphi Real World has 350+ publications in over 40 peer-reviewed journals and more than 100 scientific congresses worldwide. These publications have been used in therapy guideline evolution and regulatory submissions.

Vladimir Rogiers

Vladimir Rogiers

Vladimir Rogiers is a Senior Consultant with Across Health where he is responsible for developing integrated Pan-European multi-channel marketing plans for Across Health’s key accounts.

A self-confessed multi-channel & metrics fan, Vladimir’s key areas of expertise include CRM & customer experience, direct response campaigns, campaign localisation models, search engine marketing, data visualisation and multi-channel marketing strategy & metrics. He has over 10 years’ hands on experience in implementing and improving the multi-channel marketing capabilities of big players in the healthcare industry (e.g. Janssen) on both a local and regional level.

Vladimir joined C.E.L.forpharma’s faculty in 2016 as a co-speaker of the The Multi-Channel Patient Engagement Course which teaches how to activate patients and support them on their therapy using a multi-channel approach.